AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32171749 — intervention group
Group type: COMPARATOR
Intervention: Continuous video demonstration (1 to 2 hours preparation)
Number of subjects: 43
Study 35096134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block combined with rectus abdominis sheath block and general anesthesia
Number of subjects: 160
Study 35096134 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 160
Study 35109502 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Training (MT) intervention (2 sessions per week, 50 minutes per session for 6 months)
Number of subjects: 40
Study 35109502 — intervention group
Group type: COMPARATOR
Intervention: Control group (monthly recreational session during the same period)
Number of subjects: 40
Study 32536019 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of vaginal micronised progesterone daily (vaginal group)
Number of subjects: 266
Study 32536019 — intervention group
Group type: COMPARATOR
Intervention: 250 mg 17α-hydroxyprogesterone caproate weekly (IM group)
Number of subjects: 266
Study 34969609 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualified practitioner Johrei treatment
Number of subjects: 225
Study 34969609 — intervention group
Group type: COMPARATOR
Intervention: Non-qualified operator treatment
Number of subjects: 225
Study 34969609 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualified practitioner Johrei treatment for hypothermia tendency subjects
Number of subjects: 225
Study 34969609 — intervention group
Group type: COMPARATOR
Intervention: Non-qualified operator treatment for hypothermia tendency subjects
Number of subjects: 225
Study 34510189 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 g/d of soy nuts providing ~25.5 g protein and 174 mg isoflavones
Number of subjects: 23
Study 34510189 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 g/d of soy nuts
Number of subjects: 23
Study 34510189 — intervention group
Group type: COMPARATOR
Intervention: Control period (no nuts)
Number of subjects: 23
Study 34798600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior entry site for shunt placement
Number of subjects: 467
Study 34798600 — intervention group
Group type: COMPARATOR
Intervention: Posterior entry site for shunt placement
Number of subjects: 467
Study 34798600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anterior and posterior entry sites
Number of subjects: 467
Study 35709019 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid therapy
Number of subjects: 1554
Study 35709019 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid therapy
Number of subjects: 1554
Study 32095401 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 60
Study 32095401 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 60
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered daily low-intensity pulsed ultrasound
Number of subjects: 428
Study 33196584 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 428
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 428
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > 30 kg/m2
Number of subjects: 428
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of disability benefits or involvement in litigation
Number of subjects: 428
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 428
Study 33196584 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's advice to partially or fully bear weight postoperatively
Number of subjects: 428
Study 35993875 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 35993875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33439978 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 0 mg folic acid
Number of subjects: 331
Study 33439978 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 0.4 mg folic acid
Number of subjects: 331
Study 33439978 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe as ferrous fumarate with 2.8 mg folic acid
Number of subjects: 331
Study 33439978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 331
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐steroidal anti‐inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐17 blockade
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐23 blockade
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK pathway alteration
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE‐4 inhibition
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 blockade
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐cell co‐stimulation blockade
Number of subjects: 0
Study 32885389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination biologic therapy
Number of subjects: 0
Study 36451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 27
Study 36451130 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study 35058800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Intermittent Hypoxia (MIH) exposure (FiO2 15%, 3x2h/d)
Number of subjects: 0
Study 35058800 — intervention group
Group type: COMPARATOR
Intervention: Normoxia exposure (FiO2 21%)
Number of subjects: 0
Study 35091727 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle device delivered topical steroids
Number of subjects: 25
Study 35091727 — intervention group
Group type: COMPARATOR
Intervention: Topical Daivobet gel (control)
Number of subjects: 25
Study 34450257 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga and mindfulness-based programme (16 weeks)
Number of subjects: 40
Study 34450257 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary school lessons
Number of subjects: 40
Study 35452365 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 68
Study 35452365 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 34029296 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exercise supervision (SUP; n=21)
Number of subjects: 56
Study 34029296 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-personal exercise supervision (NPS; n=19)
Number of subjects: 56
Study 34029296 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n=16)
Number of subjects: 56
Study 32805133 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB) plus medical therapy (MT)
Number of subjects: 100
Study 32805133 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 100
Study 35623596 — intervention group
Group type: EXPERIMENTAL
Intervention: High sun exposure (≥ 15 h/week)
Number of subjects: 5039
Study 35623596 — intervention group
Group type: COMPARATOR
Intervention: Low sun exposure (< 15 h/week)
Number of subjects: 5039
Study 33750376 — intervention group
Group type: EXPERIMENTAL
Intervention: Paula Exercise Method (PEM)
Number of subjects: 182
Study 33750376 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 182
Study 32544925 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor (KOR) antagonist for 8 weeks
Number of subjects: 0
Study 32544925 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 0
Study 32544925 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa-opioid receptor (KOR) antagonist
Number of subjects: 0
Study 34348227 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) exercise (16 weeks, 3 × 20 min/week, starting with 5 × 1 min bouts at 6 Hz/2 mm, progressing to 10 × 1 min at up to 26 Hz/4 mm)
Number of subjects: 117
Study 34348227 — intervention group
Group type: COMPARATOR
Intervention: Simulated exercise (SIM) (16 weeks, 3 × 20 min/week, mimicking exercise stance and duration)
Number of subjects: 117
Study 34348227 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular care only)
Number of subjects: 117
Study 33792952 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-resource conditions
Number of subjects: 0
Study 33792952 — intervention group
Group type: COMPARATOR
Intervention: Closed-resource conditions
Number of subjects: 0
Study 32192678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low level tragus stimulation (LLTS) at 20 Hz, 1 mA below discomfort threshold for 1 hour daily over 6 months
Number of subjects: 53
Study 32192678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low level tragus stimulation (LLTS)
Number of subjects: 53
Study 32192678 — intervention group
Group type: COMPARATOR
Intervention: Sham control stimulation
Number of subjects: 53
Study 33247624 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
Number of subjects: 80
Study 33247624 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 80
Study 33247624 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 and change in NT-pro-BNP
Number of subjects: 80
Study 33247624 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (NT-pro-BNP and galectin-3)
Number of subjects: 80
Study 33247624 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP and galectin-3
Number of subjects: 80
Study 32448804 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with apatinib (continuous dosing)
Number of subjects: 40
Study 32448804 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with apatinib (intermittent dosing)
Number of subjects: 40
Study 35468658 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable selection procedure in semiparametric regression models for longitudinal data with informative observation times
Number of subjects: 0
Study 33358692 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethine/mechlorethamine gel
Number of subjects: 0
Study 36300769 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 277
Study 34075780 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 404
Study 34822214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (1 mg/kg)
Number of subjects: 59
Study 34822214 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac (0.5 mg/kg)
Number of subjects: 59
Study 35266779 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (45 mg/day)
Number of subjects: 15
Study 35266779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35774632 — intervention group
Group type: EXPERIMENTAL
Intervention: Global osteopathic protocol (myofascial, visceral, and articular techniques)
Number of subjects: 51
Study 35774632 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation technique (high-velocity, low-amplitude/thrust) of the sacroiliac joint and T10-L2
Number of subjects: 51
Study 35774632 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of the pelvic floor muscles
Number of subjects: 51
Study 35774632 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 51
Study 35226276 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg of elemental zinc daily for 24 weeks)
Number of subjects: 69
Study 35226276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 32224022 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises for 30 minutes
Number of subjects: 58
Study 32224022 — intervention group
Group type: COMPARATOR
Intervention: Control group (rested)
Number of subjects: 58
Study 34460098 — intervention group
Group type: EXPERIMENTAL
Intervention: FallTIPS fall prevention program
Number of subjects: 298
Study 34048680 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD (among PET-2-negative patients)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: COMPARATOR
Intervention: ABVD (among PET-2-negative patients)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD (among PET-2-positive patients)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: COMPARATOR
Intervention: ABVD (among PET-2-positive patients)
Number of subjects: 1334
Study 34048680 — intervention group
Group type: EXPERIMENTAL
Intervention: A+AVD
Number of subjects: 1334
Study 34048680 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1334
Study 32072216 — intervention group
Group type: EXPERIMENTAL
Intervention: Subbrow blepharoplasty combined with periorbital muscle manipulation (SBB‐pm)
Number of subjects: 70
Study 32072216 — intervention group
Group type: COMPARATOR
Intervention: Subbrow blepharoplasty (SBB)
Number of subjects: 70
Study 616191571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol (200/400/600/800/1000 mug, flexible titration, QD)
Number of subjects: 76
Study 616191571 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate prolonged release (previous treatment)
Number of subjects: 76
Study 34670008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (50, 100, 200, and 400 mg)
Number of subjects: 0
Study 34670008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33057829 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable dermal stapler
Number of subjects: 30
Study 33057829 — intervention group
Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 30
Study 32641094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized malaria rapid diagnostic test (mRDT) kits introduced after training of OTCMS
Number of subjects: 13
Study 32641094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study 35131740 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention Team (BIT)
Number of subjects: 3800
Study 35131740 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3800
Study 36182235 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partner therapy (usual care plus an offer of accelerated partner therapy)
Number of subjects: 1536
Study 36182235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1536
Study 36182235 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partner therapy
Number of subjects: 1536
Study 32986293 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down tilt 15° (HDT15°) for 1 hour
Number of subjects: 64
Study 32986293 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down tilt 15° (HDT15°)
Number of subjects: 64
Study 32986293 — intervention group
Group type: COMPARATOR
Intervention: Flat position (control)
Number of subjects: 64
Study 35090531 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMA strategy (ready-to-use therapeutic food at gradually tapered doses)
Number of subjects: 567
Study 35090531 — intervention group
Group type: EXPERIMENTAL
Intervention: ComPAS strategy (ready-to-use therapeutic food at gradually tapered doses)
Number of subjects: 567
Study 35090531 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional protocol of Niger
Number of subjects: 567
Study 35090531 — intervention group
Group type: EXPERIMENTAL
Intervention: All strategies (OptiMA, ComPAS, Standard)
Number of subjects: 567
Study 33733692 — intervention group
Group type: EXPERIMENTAL
Intervention: IV plus IVT treatment
Number of subjects: 74
Study 33733692 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotic treatment
Number of subjects: 74
Study 32912971 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment (oestradiol hemihydrate 10 μg vaginal pessaries)
Number of subjects: 100
Study 32912971 — intervention group
Group type: COMPARATOR
Intervention: No oestrogen treatment
Number of subjects: 100
Study 36286256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased early mobilization (sedation minimization and daily physiotherapy)
Number of subjects: 750
Study 36286256 — intervention group
Group type: COMPARATOR
Intervention: Usual care (normal level of mobilization in each ICU)
Number of subjects: 750
Study 36286256 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased early mobilization
Number of subjects: 750
Study 36286256 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study 33761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy
Number of subjects: 18
Study 33761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 18
Study 33761016 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PRP formulas (PRF, PRGF)
Number of subjects: 18
Study 33761016 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP therapy in degenerative disc disease, facet arthropathy, and sacroiliitis
Number of subjects: 18
Study 32527065 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 2670
Study 32527065 — intervention group
Group type: COMPARATOR
Intervention: Non-CHMs
Number of subjects: 2670
Study 34117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly progressive resistance training (PRT) and daily swallowing exercises throughout treatment
Number of subjects: 240
Study 34117531 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 34064996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of leucine
Number of subjects: 15
Study 34064996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of isoleucine
Number of subjects: 15
Study 34064996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of valine
Number of subjects: 15
Study 34064996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 35759349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 31
Study 35759349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33097384 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Kidney Care (HBKC)
Number of subjects: 63
Study 33097384 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 63
Study 36280033 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency laparoscopic appendectomy
Number of subjects: 0
Study 36280033 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 0
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 at 0.08% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 at 0.18% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 at 0.23% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 at 0.33% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2SO4 at 0.08% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2SO4 at 0.18% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2SO4 at 0.23% Na
Number of subjects: 576
Study 33485831 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2SO4 at 0.33% Na
Number of subjects: 576
Study 35191141 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 20 weeks
Number of subjects: 208
Study 35191141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 208
Study 34337905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU of colecalciferol monthly)
Number of subjects: 21315
Study 34337905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21315
Study 32481345 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (IKT)
Number of subjects: 60
Study 32481345 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization training (CST)
Number of subjects: 60
Study 32481345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 34998508 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TXA 1 g
Number of subjects: 15
Study 34998508 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. TXA 1 g
Number of subjects: 15
Study 34998508 — intervention group
Group type: EXPERIMENTAL
Intervention: oral TXA solution 2 g
Number of subjects: 15
Study 33571267 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron containing micronutrient powder supplementation (12.5 mg elemental iron, vitamin A 400 μg, ascorbic acid 30 mg, zinc 5 mg)
Number of subjects: 1958
Study 33571267 — intervention group
Group type: COMPARATOR
Intervention: Placebo micronutrient powder (without iron)
Number of subjects: 1958
Study 33571267 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron containing micronutrient powder supplementation
Number of subjects: 1958
Study 32604255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-type (IT) aerobic exercise program
Number of subjects: 72
Study 32604255 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-type (CT) aerobic exercise program
Number of subjects: 72
Study 32604255 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise (HE) program
Number of subjects: 72
Study 34625784 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 MRDhigh (defined as a WT1 MRD ratio >2.5% in bone marrow or >0.5% in peripheral blood)
Number of subjects: 314